Dr. Robert Spiera, MD
Claim this profileHospital for Special Surgery
Studies Scleroderma
Studies Systemic Scleroderma
5 reported clinical trials
5 drugs studied
Affiliated Hospitals
Clinical Trials Robert Spiera, MD is currently running
Belimumab
for Systemic Sclerosis Interstitial Lung Disease
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
Recruiting1 award Phase 311 criteria
HZN-825
for Systemic Sclerosis
This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Baseline (Day 1) Visit. Approximately 300 participants who meet the trial eligibility criteria will be randomized on Day 1 in a 1:1:1 ratio to receive HZN-825 300 mg QD, HZN-825 300 mg BID or placebo for 52 weeks. The trial will include up to a 42-day Screening Period and a 52-week Double-blind Treatment Period. Participants will take their first dose of trial drug at the clinic and will participate in trial visits at Week 4 and every 6 weeks thereafter until Week 52. All participants who complete the Double-blind Treatment Period (Week 52) will be eligible to enter a 52-week extension trial (HZNP-HZN-825-302, NCT05626751). Participants not entering the extension trial will participate in a Safety Follow-up Visit 4 weeks after the last dose of trial drug.
Recruiting0 awards Phase 26 criteria
More about Robert Spiera, MD
Clinical Trial Related5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Robert Spiera, MD has experience with
- Placebo
- Belumosudil (KD025)
- Abatacept
- HZN-825
- Belimumab
Breakdown of trials Robert Spiera, MD has run
Scleroderma
Systemic Scleroderma
Multiple Sclerosis
Systemic Sclerosis
Localized Scleroderma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert Spiera, MD specialize in?
Robert Spiera, MD focuses on Scleroderma and Systemic Scleroderma. In particular, much of their work with Scleroderma has involved treating patients, or patients who are undergoing treatment.
Is Robert Spiera, MD currently recruiting for clinical trials?
Yes, Robert Spiera, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Robert Spiera, MD has studied deeply?
Yes, Robert Spiera, MD has studied treatments such as Placebo, Belumosudil (KD025), Abatacept.
What is the best way to schedule an appointment with Robert Spiera, MD?
Apply for one of the trials that Robert Spiera, MD is conducting.
What is the office address of Robert Spiera, MD?
The office of Robert Spiera, MD is located at: Hospital for Special Surgery, New York, New York 10021 United States. This is the address for their practice at the Hospital for Special Surgery.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.